HomeRELAXO › Filing
🔔 Get instant alerts when RELAXO files quarterly results on BSE Start free trial →

Investor Presentation

Filed: 13 Aug 2026, 17:32 IST Exchange: NSE Category: Financial Results — Investor Presentation
Investor Presentation - Q1FY27 - Revenue 705 Cr +7.7% y-y; EBITDA 108 Cr (margin 15.4%, +15 bps y-y); PAT 55 Cr +12.4% y-y - Q1FY27 pairs sold 4.2 Cr vs 4.3 Cr in Q1FY26; average realization per pair increased to ₹166 - EBITDA margin improved slightly to 15.4% in Q1FY27 from 15.2% in Q1FY26 - PAT margin improved to 7.8% from 7.5% y-y - Company is upgrading manufacturing capacity, recalibrated daily capacity to 9.1 lakh pairs - Indian footwear market expected to grow at 9.7% CAGR to ₹4,433 Bn by 2034 - Strong distribution with 70,000+ retailers and 429 exclusive brand outlets - Net debt reduced to ₹206 Cr in FY26 from ₹292 Cr in FY25 - ROE steady at 8.3% and ROCE at 12.1% in FY26
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 RELAXO — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add RELAXO to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Relaxo Footwears Limited

Important. The summary above is generated automatically from Relaxo Footwears Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.